Carregant...

IMMU-17. REDUCING THE EX VIVO MANUFACTURING TIME OF EGFRVIII-SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS IMPROVES PHENOTYPE AND DEMONSTRATES POTENT ANTI-GLIOMA FUNCTION IN VIVO

Chimeric antigen receptor (CAR) T-cell therapy for glioma has been developed that targets EGFRvIII, HER2, EphA2, and IL13Rα2 antigens. Epidermal growth factor receptor variant III (EGFRvIII) is an attractive target for CAR therapy because its expression is tumor-restricted. Non-viral manufacturing o...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Tanaka, Ryuma, Caruso, Hillary, Ling, Xiaoyang, Najjar, Amer, Heimberger, Amy
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2017
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692930/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.476
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!